SEC Filing Summary: Rexahn Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Rexahn Pharmaceuticals, Inc. on March 26, 2010, regarding an event that occurred on March 24, 2010. The filing addresses corporate governance changes rather than operational or financial performance updates. Note: The request metadata references "Opus Genetics, Inc.," but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific corporate action and does not contain financial statements or performance data.
Material Changes
The Board of Directors approved an immediate amendment to the Company's Amended and Restated Bylaws. Specifically, Article II, Section 6 (Quorum) was modified to lower the quorum requirement for stockholder meetings from a majority of issued and outstanding stock to forty percent (40%) of issued and outstanding stock.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document focuses solely on the procedural change to the Bylaws.
Investor Verification Checklist
- Verify the exact text of the Amended and Restated Bylaws attached as Exhibit 3.1 to confirm the new 40% quorum threshold.
- Confirm the effective date of the amendment (March 24, 2010) for any upcoming stockholder meetings.
- Review subsequent filings to determine if this governance change impacts the company's ability to pass future resolutions.